NeuroSense Therapeutics(US:NRSN) Prnewswire·2026-02-09 14:20Core Viewpoint - NeuroSense Therapeutics has strengthened its global intellectual property portfolio for its lead drug candidate PrimeC by securing an Australian patent, which complements an existing U.S. patent and extends exclusivity through October 2042 [1][2][3]. Group 1: Intellectual Property and Patent Strategy - The Australian Patent Office granted Australian Patent No. 2022370513 for PrimeC, which is a significant addition to NeuroSense's global patent protection strategy [1][2]. - The granted patent in Australia follows the approval of the corresponding U.S. patent (12,097,185), enhancing NeuroSense's exclusivity strategy for PrimeC across key global markets [2][3]. - CEO Alon Ben-Noon emphasized that securing patent protection in Australia is crucial for executing the company's global IP protection strategy for PrimeC, which is essential for long-term value creation [3]. Group 2: Product Development and Clinical Readiness - PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to target multiple disease pathways implicated in ALS and Alzheimer's disease [3][7]. - The formulation of PrimeC allows for consistent exposure across various disease pathways, supporting a multi-target disease-modifying approach [3]. - PrimeC is now Phase 3-ready in ALS, following positive results from the Phase 2b PARADIGM trial and FDA clearance of the pivotal Phase 3 protocol [4]. Group 3: Market Context and Unmet Medical Needs - Neurodegenerative diseases, including ALS and Alzheimer's, represent significant unmet medical needs, with limited effective therapeutic options currently available [5]. - ALS affects over 5,000 people annually in the U.S., with a substantial disease burden estimated at $1 billion per year [8]. - Alzheimer's disease impacts more than 30 million people globally, characterized by memory loss and cognitive decline, with a pressing need for disease-modifying treatments [10].